Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Drug Brings Hope for Liver Cancer Patients (China)

This article was originally published in PharmAsia News

Executive Summary

An ongoing study conducted by HKU Li Ka Shing Faculty of Medicine and Queen Mary Hospital in Hong Kong has used Sorafenib on 50 advanced liver cancer patients. The drug is developed by German pharmacy group Bayer AG. In the first trial of Sorafenib on 16 Hong Kong patients, conditions of 13 and 25 percent have improved and stabilized respectively after their tumor growth was reassessed by CT scan after three months. A new drug that targets molecular pathways of cancer, Sorafenib hinders both tumor cell proliferation and a protein known as vascular endothelial growth factor. "Without using the drug, most of these patients could have died within three months after diagnosed with advanced liver cancer," says Professor Ronnie Poon Tung-ping of the Department of Surgery, HKU Li Ka Shing Faculty of Medicine. "Unlike other cancers such as breast cancer, there is no systemic therapy for liver cancer and it is resistant to conventional chemotherapy," he adds. "Compared to conventional chemotherapy, the drug is safe and has simpler curing process." (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts